Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans.

Authors

Aditya Barve, Preeti Dabas, Adam Cornwell, Pramika Sriram, Alex Kopyov, Mattieu Zhai, Emilia Kooienga, Zakiya Kelley, James Johnson, Jacquelyn A Myers, Esther A Obeng, Guolian Kang, Yunusa Olufadi, Terri Cain, Lindsay Talbot, David Spence, Mauricio Cortes, Samuel A Miller, Dirk Loeffler, Akshay Sharma, Shannon McKinney-Freeman

Published in

Science translational medicine. Volume 18. Issue 859. Pages eadv0628. Jul 22, 2026. Epub Jul 22, 2026.

Abstract

Sickle cell disease (SCD) is a blood disorder affecting millions worldwide. Emerging evidence reveals that SCD pathophysiology increases the risk of myeloid malignancies and hematopoietic stem cell (HSC) dysfunction, likely because of chronic stress on bone marrow. To investigate this further, we interrogated bone marrow hematopoietic stem and progenitor cells (HSPCs) from mice and individuals with SCD and observed molecular signatures of chronic cellular stress including oxidative stress, DNA damage, and hallmarks of senescence. Consistent with these findings, SCD HSPCs displayed transcriptomic dysregulation of senescence-associated molecular programs and diminished mitogen response with prolonged cell cycle kinetics during time-lapse live cell imaging. SCD mice displayed a marked loss of immunophenotypic bone marrow HSPCs by flow cytometry and functional blood repopulating HSPCs in transplantation studies, whereas human SCD bone marrow HSPCs exhibited poor ex vivo hematopoietic colony-forming ability, and these phenotypes were reversed after senescence-targeting therapy with either ABT-263 (navitoclax) or the combination of dasatinib and quercetin. Thus, treatment with senescence-targeting therapy improves bone marrow HSPC function in vivo in mice and ex vivo in cells from individuals with SCD and could represent a possible strategy to improve HSPC health, promote manufacture of high-quality bespoke clinical products, and potentially enhance the safety of potentially curative gene therapies using autologous HSPCs from individuals with SCD.

PMID:
42485438
Bibliographic data and abstract were imported from PubMed on 23 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.